Chordia Therapeutics Inc. (TYO:190A)
Japan · Delayed Price · Currency is JPY 119.00
+6.00 (5.31%)
Feb 16, 2026, 3:30 PM JST
Chordia Therapeutics Company Description
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan.
It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099.
Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Chordia Therapeutics Inc.
| Country | Japan |
| Founded | 2017 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Hiroshi Miyake |
Contact Details
Address: 26-1, Muraoka-Higashi 2-chome Fujisawa, 251-0012 Japan | |
| Website | chordiatherapeutics.com |
Stock Details
| Ticker Symbol | 190A |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | September - August |
| Reporting Currency | JPY |
| ISIN Number | JP3283730004 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Hiroshi Miyake | Chief Executive Officer |